cep2563
Small moleculeexperimental
Clinical trial activity
0 trials · 0 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0
Mechanism of action
Neurotrophic tyrosine kinase receptor inhibitor
- Protein kinase C (PKC)INHIBITOR
Protein kinase C (PKC) inhibitor
- Serine/threonine-protein kinase D3 (PRKD3) ↗
- Protein kinase C iota type (PRKCI) ↗
- Protein kinase C alpha type (PRKCA) ↗
- Protein kinase C gamma type (PRKCG) ↗
- Protein kinase C delta type (PRKCD) ↗
- Protein kinase C beta type (PRKCB) ↗
- Protein kinase C zeta type (PRKCZ) ↗
- Protein kinase C epsilon type (PRKCE) ↗
- Protein kinase C eta type (PRKCH) ↗
- Serine/threonine-protein kinase D1 (PRKD1) ↗
- Protein kinase C theta type (PRKCQ) ↗
- Protein kinase C zeta
- Protein kinase C epsilon
- Protein kinase C gamma
- Protein kinase C nu
- Protein kinase C iota
- Protein kinase C mu
- Protein kinase C eta
- Protein kinase C alpha
- Protein kinase C beta
- Protein kinase C delta
- Protein kinase C theta
- Protein kinase C, PKC; classical/novel
- PKC alpha and beta-2
- Protein kinase C iota type/zeta type
FLT3 inhibitor
- Tyrosine-protein kinase receptor RETINHIBITOR
RET inhibitor
PDGFRB inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
CO[C@]1(COC(=O)CCNC(=O)C(N)CCCCN)C[C@H]2O[C@]1(C)n1c3ccccc3c3c4c(c5c6ccccc6n2c5c31)C(=O)NC4- Mol. weight
- 652.75 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Prodrug
Sources
- ChEMBLCHEMBL6069183 ↗
- ChEMBLCHEMBL5316170 ↗
- ChEMBLCHEMBL3545332 ↗
Also known as
- cep2563
- cep 2563
- cep-2563
- cep-2563
- cep-2563